key: cord-1036096-khmy9oa4
authors: Mazza, M.G.; Palladini, M.; Bravi, B.; Poletti, S.; Rovere-Querini, P.; Benedetti, F.
title: P.0267 Persistent psychopathology in covid-19 survivors at one-year follow-up
date: 2021-12-30
journal: Eur Neuropsychopharmacol
DOI: 10.1016/j.euroneuro.2021.10.254
sha: f1b8ade7c166c8ccd9f520202d0630ae825383a5
doc_id: 1036096
cord_uid: khmy9oa4

Introduction: The effects of COVID-19 are highly variable, with potential involvement of almost all organs and systems. While the acute and sub-acute symptoms have been well described, the possible long-term sequelae of COVID-19 have become an increasing concern [1]. One, three, and six-months follow-up studies have reported highly prevalent post COVID neuropsychiatric sequelae [2,3,4,5]. The aim of the present study is to investigate the psychopathological impact of COVID-19 in survivors at one-year follow-up, also considering the effect of possible risk factors. Methods: We prospectively evaluated the psychopathological status of 160 COVID-19 survivors one year after hospital discharge during an ongoing prospective cohort study. To keep a naturalistic study design, exclusion criteria were limited to patients under 18 years. Sociodemographic and clinical data were collected. Current psychopathology was measured using the following self-report questionnaire: Zung Self-Rating Depression Scale (ZSDS), Impact of Events Scale-Revised (IES-R), State-Trait Anxiety Inventory form Y (STAI-Y), and Fatigue Severity Score (FSS). Need of antidepressant or anxiolytic treatment in the last year was collected. Statistical analyses to compare group means and frequencies (Student's t-test, Pearson χ2 test) exploring effects of sex, psychiatric history, and hospitalization for COVID-19 were performed. Results: Overall, 77 patients (48%) scored in the clinical range in at least one psychopathological dimension among depression, anxiety, and PTSD. Females and patients with a positive previous psychiatric diagnosis showed an increased score on most measures (Table). Hospitalization for COVID-19 did not affect psychopathology. During the year after COVID-19, 25 (16%) and 23 (14%) patients started an antidepressant or anxiolytic treatment respectively.Discussion: This is the first study that investigates psychopathology in a sample of COVID-19 survivors at one-year follow-up after hospital treatment. We reported high rates of persistent psychopathology consistently with previous coronavirus outbreaks. Psychiatric consequences to SARS-CoV-2 infection can be caused by the immune-inflammatory response to the virus itself or by psychological stressors such as social isolation, concerns about infecting others, and stigma. Considering that neuropsychiatric sequelae associates with a markedly increased risk of all-cause mortality, and given the alarming prevalence of post-COVID psychopathology, we now suggest to routinely asses psychopathology of COVID-19 survivors in order to promptly diagnose emergent disorders and to treat them to reduce the disease burden and related years of life lived with disability. No conflict of interest

Background: Multinational studies have recently reported significantly higher rates of anxiety and depression seen in the general population, compared to pre-COVID-19pandemic levels. [1] Younger age cohorts and female sex have emerged as predictors for worse mental health (MH) and there is also evidence to suggest that the MH burden on healthcare practitioners (HCPs) is a significant cost of the pandemic. [ 2 , 3 ] Negative psychological consequences for HCPs have been highlighted in previous epidemics and pandemics including Severe Acute Respiratory Syndrome[SARS], SARS-CoV, SARS-CoV-2, H1N1, Middle East Respiratory Syndrome [MERS] and Ebola. This study aims to examine and compare the impact of COVID-19 on the MH of an international cohort from Canada, the United States of America (US), Brazil and Italy. Given that very few studies have reported this information thus far, we focused our analysis on the MH of HCPs within these countries. Methods: Adults aged 18 and over completed an online survey posted at anxiety treatment centre websites in Canada, USA, Brazil and Italy from April 8th -June 11th, 2020. The survey included questions regarding COVID-19 experience, perceived impact of the pandemic on life domains (e.g., social communication, finances), coping strategies (e.g., online activities, substance use), and MH treatment history. Current psychiatric symptom severity and impairment were evaluated using the Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, the Perceived Stress Scale, the Obsessive Compulsive Inventory-Revised (OCI-R), the PTSD Checklist (PCL-5) and the Quality of Life Enjoyment and Satisfaction Questionnaire.

Results : Overall, 1315 individuals (74% female, mean age:42.9 + 16.4) in Canada (n = 443), the USA (n = 203), Brazil (n = 517) and Italy (n = 152) completed the survey. Nearly 26% met diagnostic thresholds for GAD and MDD. Compared to the other countries, fewer Italians met DSM-5 screening criteria for GAD ( < 0.001) or depression, (p < 0.05). In addition, quality of life satisfaction scores were significantly lower in Italy and Brazil when compared to North America, (p < 0.001), indicating lower satisfaction. Non-HCPs (vs. HCPs) reported significantly higher scores (p ≤0.005) on all MH scales with the exception of the GAD-7, even after adjusting for age, sex, past MH treatment and country. Non-HCPs also reported lower quality of life. Amongst the HCPs, Canadian HCPs reported the highest rates of anxiety, depression, stress and PTSD compared to Canadian non-HCPs and to HCPs in the other countries. Higher proportions of Canadian HCPs also reported decreases in sleep, increases in eating and more time spent watching the news as well as lower levels of perceived emotional support compared to Canadian non-HCPs Conclusion: Despite key infrastructural and COVID-19 mortality differences between the countries, the MH effects appeared to be quite similar within the general populations. HCP status was associated with lower levels of stress, anxiety, depression and related symptoms, with the exception of Canada. Canadian HCPs reported higher symptom severity scores than HCPs from the remaining countries. Therefore, with the exception of Canada, HCPs reported less impact on their mental health compared to the general population, in response to the COVID-19 pandemic, potentially suggesting resilience in the face of adversity. Introduction: The effects of COVID-19 are highly variable, with potential involvement of almost all organs and systems. While the acute and sub-acute symptoms have been well described, the possible long-term sequelae of COVID-19 have become an increasing concern [1] . One, three, and six-months follow-up studies have reported highly prevalent post COVID neuropsychiatric sequelae [ 2 , 3 , 4 , 5 ] . The aim of the present study is to investigate the psychopathological impact of COVID-19 in survivors at one-year follow-up, also considering the effect of possible risk factors. Methods: We prospectively evaluated the psychopathological status of 160 COVID-19 survivors one year after hospital discharge during an ongoing prospective cohort study. To keep a naturalistic study design, exclusion criteria were limited to patients under 18 years. Sociodemographic and clinical data were collected. Current psychopathology was measured using the following self-report questionnaire: Zung Self-Rating Depression Scale (ZSDS), Impact of Events Scale-Revised (IES-R), State-Trait Anxiety Inventory form Y (STAI-Y), and Fatigue Severity Score (FSS). Need of antidepressant or anxiolytic treatment in the last year was collected. Statistical analyses to compare group means and frequencies (Student's t-test, Pearson χ 2 test) exploring effects of sex, psychiatric history, and hospitalization for COVID-19 were performed. Results: Overall, 77 patients (48%) scored in the clinical range in at least one psychopathological dimension among depression, anxiety, and PTSD. Females and patients with a positive previous psychiatric diagnosis showed an increased score on most measures (Table) . Hospitalization for COVID-19 did not affect psychopathology. During the year after COVID-19, 25 (16%) and 23 (14%) patients started an antidepressant or anxiolytic treatment respectively. Discussion: This is the first study that investigates psychopathology in a sample of COVID-19 survivors at one-year follow-up after hospital treatment. We reported high rates of persistent psychopathology consistently with previous coronavirus outbreaks. Psychiatric consequences to SARS-CoV-2 infection can be caused by the immune-inflammatory response to the virus itself or by psychological stressors such as social isolation, concerns about infecting others, and stigma.

Considering that neuropsychiatric sequelae associates with a markedly increased risk of all-cause mortality, and given the alarming prevalence of post-COVID psychopathology, we now suggest to routinely asses psychopathology of COVID-19 survivors in order to promptly diagnose emergent disorders and to treat them to reduce the disease burden and related years of life lived with disability.

macology: the official journal of the Society on NeuroImmune Pharmacology 16, 1-3.

[5] Lorenzo, R.de, Conte, C., Lanzani, C., Benedetti, F., Roveri, L., Mazza, M.G., Brioni, E., Giacalone, G., Canti, V., Sofia, V., D'Amico, M., Di Napoli, D., Ambrosio, A., Scarpellini, P., Castagna, A., Landoni, G., Zangrillo, A., Bosi, E., Tresoldi, M., Ciceri, F., Rovere-Querini, P., 2020. Background. The association between cannabis use (CU) and cognitive impairment among adolescents has been the subject of controversial debate. Previous studies on cannabis and THC exposure on DNA methylation have indicated that cannabis might affect gene expression via DNA methylation at CG dinucleotides (CpG methylation) in genes affecting neurodevelopment and neuronal signaling [1] . Linking CpG methylation to CU could help to understand changes in cognitive performance that is associated with CU. Yet no previous study has examined the epigenetic influences of high CU on performance in cognitive tasks in adolescents with cannabis use disorders.

Methods. The sample consisted of n = 18 adolescents, n = 9 with CU and n = 9 without, matched on age (M (17) = 15.6, SD = 1.5), gender (78% males) and (comorbid) psychiatric disorders (M (17) = 0.9, SD = 1.4). We analyzed DNA methylation at approximately 850,000 CG dinucleotides (CpG sites) in peripheral whole-blood, selfreported past-year CU via a Quantity-Frequency-Index, and cognitive task performances and comorbid psychiatric disorders via Mini International Neuropsychiatric Interview for Children and Adolescents. The cognitive tasks consisted of consisting of a verbal learning memory task (VLMT), inhibitory control tasks, divided attention and alertness tasks. Correlation analyses were performed between CU and cognitive task performance and CU and CpG sites in order to identify CU associated CpG sites. After correcting for multiple testing (Bonferroni) mediation analyses were performed to test whether relationships between CU and performance in cognitive tasks was mediated by methylation in specific CpG sites.

Results. Methylation in six CpG sites (associated with the genes SH3PXD2B, DGCR8, ZNF107, SNX15/SAC3D1, EPN2 and an intergenic CpG) were significantly associated with pastyear CU (r = -.93 to -.95; p = 3.78 -8 -1.20 -9 ). Notably, all genes that are associated with methylation of the six identified CpG sites have previously been associated with processes involved in cognition and memory. CU was associated with two variables in cognitive tasks, 1) the total score in a verbal learning task in which a word list was learned and repeated five times and 2) verbal learning cued recall, in which the learned words had to be identified among distractor words. All six CpG sites mediated the effects between CU and verbal learning total score (R ² = 85.6% -90.6%; c' = -0.16 --0.22; Z = -2.01 --2.86; p (Z) = .045 -.004). No mediation effects were found for verbal learning cued recall.

Conclusions. Our results indicate that CU might affect memory function via CpG methylation at genes involved in hippocampal (EPN2, SNX15, DGCR8) and general neurogenesis (SH3PXD2B, SAC3D1) in adolescents with cannabis use disorders. Further, DGCR8 has been postulated a candidate for 22q11.2 deletion-associated schizophrenia, which is one of the highest known genetic risk factors for developing schizophrenia [2] . Future studies should replicate these findings with larger sample sizes and additionally measure mRNA and protein expression.

Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors

Sperm DNA methylation altered by THC and nicotine: Vulnerability of neurodevelopmental genes with bivalent chromatin

Neurodevelop

The authors declare the following financial interests/personal relationships which may be considered as potential conflicts of interest: SKP reports grants and non-financial support during the past 36 months from German Federal Ministry of Health (BMG), personal fees from IAP-TUD GmbH, personal fees from Carus Vital GmbH, personal fees from Berufsverband der Pneumologen in Sachsen e.V., personal fees from Gesundheitsamt Dresden as funded by the German Federal Centre for Health Education (BzgA), personal fees from Mabuse Verlag, personal fees from a consortium funding a public speach (AbbVie Germany, Almirall Hermal, Belano medical, Celgene, Janssen-Cilag, LEO Pharma, Lilly Germany, Novartis Pharma, Pfizer Pharma, UCB Pharma), and non-financial support from College on Problems of Drug Dependence (CPDD), all outside of the submitted work. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals/Takeda, and Medice Pharma, and support for research from Shire Pharmaceuticals/Takeda and Novartis. VR has carried out or is currently carrying out clinical trials in cooperation with the Novartis, Shire Pharmaceuticals/Takeda, Servier and Otsuka companies. WW is cofounder of Cygenia GmbH (www.cygenia.com), which provides service for epigenetic analysis to other scientists and was involved in this study. JF contributes to this company, too. MW, LB and YG declare no competing interests. This study was funded by the Sächsische Aufbaubank -Förderbank-, (grant 100362999 to YG).